Zymeworks Inc
For the period ended Sep 30, 2024. Filed Oct 31, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Oct 31, 2024
ZYME$31.46+2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(Expressed in thousands of U.S. dollars)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(99,189) | $(104,192) |
| Items not involving cash: | ||
| Depreciation of property and equipment | 3,191 | 5,926 |
| Amortization of intangible assets | 2,494 | 2,029 |
| Stock-based compensation expense | 12,771 | 4,732 |
| Amortization of operating lease right-of-use assets | 1,819 | 6,002 |
| Impairment of acquired IPR&D (note 6) | 17,287 | — |
| Deferred income tax (recovery) expense | (436) | 210 |
| Change in fair value of contingent consideration liability | (1,878) | 331 |
| Unrealized foreign exchange gain | (588) | (384) |
| Changes in non-cash operating working capital: | ||
| Accounts receivable | (4,729) | (33,873) |
| Prepaid expenses and other current assets | (4,159) | 11,976 |
| Accounts payable and accrued liabilities | 6,997 | (22,468) |
| Operating lease liabilities | (7,531) | (2,630) |
| Deferred revenue and other consideration | 5,154 | 93 |
| Income taxes payable | 261 | (9) |
| Net cash used in operating activities | (68,536) | (132,257) |
| Cash flows from financing activities: | ||
| Proceeds from issuance of common stock under at-the-market program and from public offerings, net of issuance costs (notes 8a) | — | 26,233 |
| Issuance of common stock on exercise of stock options | 8,072 | 4,236 |
| Issuance of common stock through employee stock purchase plan | 930 | 820 |
| Purchases of common stock for retirement | (20,624) | — |
| Deferred financing fees | (174) | (39) |
| Finance lease payments | (12) | (14) |
| Net cash (used in) provided by financing activities | (11,808) | 31,236 |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (229,923) | (491,340) |
| Proceeds from marketable securities | 277,645 | 287,747 |
| Acquisition of property and equipment | (1,677) | (2,118) |
| Acquisition of intangible assets | (1,075) | (205) |
| Net cash provided by (used in) investing activities | 44,970 | (205,916) |
| Effect of exchange rate changes on cash and cash equivalents | 173 | 357 |
| Net change in cash and cash equivalents | (35,201) | (306,580) |
| Cash and cash equivalents, beginning of period | 157,557 | 400,912 |
| Cash and cash equivalents, end of period | $122,356 | $94,332 |
| Supplemental disclosure of non-cash investing and financing items: | ||
| Leased assets obtained in exchange for operating lease liabilities | $644 | $922 |
| Acquisition of property and equipment and intangible assets in accounts payable and accrued liabilities | — | 1,073 |
| Purchases of common stock not settled | 500 | — |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.